1,106
Participants
Start Date
September 6, 2016
Primary Completion Date
January 22, 2021
Study Completion Date
March 23, 2021
Thymosin alpha 1
Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Placebo
Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Chinese PLA General Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Shanghai Ruijin Hospital, Shanghai
Shanghai Zhongshan Hospital, Fudan University, Shanghai
Nanjing General Hospital of Nanjing Military Commend, Nanjing
Shandong Provincial Hospital, Jinan
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Hospital, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
Guangzhou First People's Hospital, Guangzhou
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
The First People's Hospital of Foshan, Foshan
West China Hospital, Sichuan University, Chengdu
Qingyuan People's Hospital, Qingyuan
Peking University Shenzhen Hospital, Shenzhen
Zhuhai People's Hospital, Zhuhai
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an
Beijing Friendship Hospital, Capital Medical University, Beijing
Collaborators (1)
SciClone Pharmaceuticals
INDUSTRY
Sun Yat-sen University
OTHER